Our top pick for
Kadant Inc is a specialty industrial machinery business based in the US. Kadant shares (KAI) are listed on the NYSE and all prices are listed in US Dollars. Kadant employs 2,800 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$208.12|
|52-week range||$108.53 - $225.36|
|50-day moving average||$211.33|
|200-day moving average||$188.08|
|Wall St. target price||$213.33|
|Dividend yield||$0.98 (0.48%)|
|Earnings per share (TTM)||$6.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||4.02%|
|1 month (2021-09-20)||-2.75%|
|3 months (2021-07-20)||19.02%|
|6 months (2021-04-20)||15.76%|
|1 year (2020-10-19)||77.27%|
|2 years (2019-10-18)||139.11%|
|3 years (2018-10-19)||112.45%|
|5 years (2016-10-19)||293.94%|
Valuing Kadant stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kadant's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kadant's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Kadant shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Kadant's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.2291. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kadant's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Kadant's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $135.4 million.
The EBITDA is a measure of a Kadant's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$691.3 million|
|Operating margin TTM||15.02%|
|Gross profit TTM||$277.3 million|
|Return on assets TTM||6.67%|
|Return on equity TTM||14.66%|
|Market capitalisation||$2.4 billion|
TTM: trailing 12 months
There are currently 171,615 Kadant shares held short by investors – that's known as Kadant's "short interest". This figure is 1% up from 169,942 last month.
There are a few different ways that this level of interest in shorting Kadant shares can be evaluated.
Kadant's "short interest ratio" (SIR) is the quantity of Kadant shares currently shorted divided by the average quantity of Kadant shares traded daily (recently around 37388.888888889). Kadant's SIR currently stands at 4.59. In other words for every 100,000 Kadant shares traded daily on the market, roughly 4590 shares are currently held short.
However Kadant's short interest can also be evaluated against the total number of Kadant shares, or, against the total number of tradable Kadant shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kadant's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Kadant shares in existence, roughly 10 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable Kadant shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kadant.
Find out more about how you can short Kadant stock.
Dividend payout ratio: 15.74% of net profits
Recently Kadant has paid out, on average, around 15.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Kadant shareholders could enjoy a 0.49% return on their shares, in the form of dividend payments. In Kadant's case, that would currently equate to about $0.98 per share.
While Kadant's payout ratio might seem low, this can signify that Kadant is investing more in its future growth.
Kadant's most recent dividend payout was on 10 November 2021. The latest dividend was paid out to all shareholders who bought their shares by 12 October 2021 (the "ex-dividend date").
Kadant's shares were split on a 1:5 basis on 11 July 2001. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kadant shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Kadant shares which in turn could have impacted Kadant's share price.
Over the last 12 months, Kadant's shares have ranged in value from as little as $108.5273 up to $225.3574. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Kadant's is 1.3153. This would suggest that Kadant's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kadant Inc. supplies critical components and engineered systems worldwide. It operates through three segments: Flow Control, Industrial Processing, and Material Handling. The Flow Control segment develops, manufactures, and markets fluid-handling systems and equipment, such as rotary joints, syphons, turbulator bars, expansion joints, and engineered steam and condensate systems; and doctoring, cleaning, and filtration systems and related consumables, consisting of doctor systems and holders, profiling systems, doctor blades, shower and fabric-conditioning systems, formation systems, and water-filtration systems. The Industrial Processing segment develops, manufactures, and markets ring and rotary debarkers, stranders, chippers, logging machinery, industrial automation and control systems, recycling and approach flow systems, and virgin pulping process equipment for use in the packaging, tissue, wood products, and alternative fuel industries. The Material Handling segment offers conveying and vibratory equipment, and balers and related equipment; and manufactures and sells biodegradable absorbent granules for carriers in as carriers in agricultural, home lawn and garden, professional lawn, turf, and ornamental applications, as well as for oil and grease absorption. The company was formerly known as Thermo Fibertek Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.